Fast discharge after heart attack treatment
Fast Discharge After Acute Myocardial Infarction Discharge MI - A Randomized Multicenter Non Inferiority Trial
This study is testing if patients who have a heart attack can safely leave the hospital just 24 hours after treatment instead of the usual 72 hours.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 2070 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University Innsbruck Academic / other |
| Locations | 8 sites (Wiener Neustadt, Lower Austria and 7 other locations) |
| Trial ID | NCT06744322 on ClinicalTrials.gov |
What this trial studies
This trial evaluates whether a fast discharge strategy, allowing patients to leave the hospital 24 hours after treatment for acute myocardial infarction, is as safe as the standard discharge time of 72 hours. It is a randomized, multicenter trial that focuses on patients who have undergone invasive management for their heart condition. The primary goal is to assess the risk of major adverse cardiovascular events within 12 months following discharge. By comparing these two discharge strategies, the study aims to determine if quicker discharge can be safely implemented without increasing risks.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have experienced an uncomplicated acute myocardial infarction and have undergone successful invasive management.
Not a fit: Patients with complicated myocardial infarctions, such as those who experienced cardiac arrest or malignant arrhythmias, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to shorter hospital stays for heart attack patients without compromising their safety.
How similar studies have performed: Other studies have explored early discharge strategies for heart attack patients, showing promising results, but this specific approach is being evaluated for the first time in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC * Age ≥ 18 years at time of consent * Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-interventional TIMI 3 flow * Ability to understand and willingness to sign and date written informed consent Exclusion Criteria: * Myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest/in-hospital cardiac arrest) * PCI-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade ≥2, stroke/thromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage and arterial dissection/occlusion or emboli) * Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (\< 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- /third-degree atrioventricular block) after PCI * Ongoing hemodynamic instability (systolic blood pressure \<90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors) * Ongoing respiratory instability defined by Killip class \>I (rales, pulmonary edema) * Ongoing quantitative disorders of consciousness (somnolence, sopor, coma) * Acute kidney injury defined by Kidney Disease Improving Global Outcomes (KDIGO) stages 2 and 3 * Pregnancy * Untreated critical non-culprit lesions requiring revascularization during index hospitalization not allowing fast discharge * Immobility/limited mobility or social circumstances that prevent fast discharge assessed by an interprofessional care team
Where this trial is running
Wiener Neustadt, Lower Austria and 7 other locations
- Hospital Wiener Neustadt — Wiener Neustadt, Lower Austria, Austria (Recruiting)
- Cardinal Schwarzenberg Hospital Schwarzach — Schwarzach im Pongau, Schwarzach Im Pongau, Austria (Not_yet_recruiting)
- Paracelsus Medical University Salzburg — Salzburg, State of Salzburg, Austria (Recruiting)
- Medical University of Graz — Graz, Styria, Austria (Recruiting)
- Medical University of Innsbruck — Innsbruck, Tyrol, Austria (Recruiting)
- University Teaching Hospital Wels-Grieskirchen — Wels, Upper Austria, Austria (Recruiting)
- Academic Teaching Hospital Feldkirch — Feldkirch, Vorarlberg, Austria (Recruiting)
- Ludwig Maximilian University Munich — Munich, Bavaria, Germany (Not_yet_recruiting)
Study contacts
- Principal investigator: Martin Reindl, MD, PhD — Medical University Innsbruck
- Study coordinator: Martin Reindl, MD, PhD
- Email: martin.reindl@tirol-kliniken.at
- Phone: +43 512 504 25665
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.